Dividend Assets Capital LLC grew its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 15.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,602 shares of the biopharmaceutical company’s stock after buying an additional 5,590 shares during the quarter. Dividend Assets Capital LLC’s holdings in Pfizer were worth $1,431,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the business. Shine Investment Advisory Services Inc. bought a new stake in shares of Pfizer in the 2nd quarter valued at about $102,000. D. Scott Neal Inc. raised its holdings in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new stake in shares of Pfizer in the 1st quarter valued at about $121,000. Cascade Investment Advisors Inc. raised its holdings in shares of Pfizer by 89.1% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 2,200 shares during the period. Finally, Perennial Advisors LLC raised its holdings in shares of Pfizer by 7.9% in the 2nd quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 376 shares during the period. 69.36% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The disclosure for this sale can be found here. Insiders sold 374,621 shares of company stock valued at $12,796,098 over the last 90 days. Corporate insiders own 0.06% of the company’s stock.
Pfizer, Inc. (NYSE PFE) opened at $35.38 on Wednesday. Pfizer, Inc. has a 52 week low of $30.51 and a 52 week high of $36.78. The firm has a market cap of $210,412.95, a price-to-earnings ratio of 14.12, a P/E/G ratio of 2.50 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter last year, the firm earned $0.61 earnings per share. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. analysts expect that Pfizer, Inc. will post 2.6 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.62%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is 79.01%.
A number of equities research analysts have recently issued reports on PFE shares. Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $38.00 to $36.00 in a report on Thursday, July 20th. UBS AG reiterated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research note on Monday, July 31st. Berenberg Bank set a $39.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, August 1st. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and upped their price target for the company from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Finally, Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. Pfizer currently has a consensus rating of “Hold” and a consensus price target of $38.48.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.